Odaia, a Toronto, Canada-based developer of an AI-powered commercial insights SaaS platform for pharmaceutical companies, raised $25M in Series B funding.
The round was led by Threshold Ventures and Monograph Capital. Backers included Wittington Ventures and existing investors Flint Capital, BDC Capital’s Women in Technology Venture Fund, StandUp Ventures and Graphite Ventures. Emily Melton, Managing Partner of Threshold Ventures and Charles Conn, co-founder and Partner of Monograph Ventures, will join ODAIA’s board. Megan Kelly, Principal of Threshold Ventures, will also join as a board observer.
The company intends to use the funds to evolve its product and build out its team.
Led by Philip Poulidis, CEO and Co-Founder, Odaia provides Maptual, an AI-powered commercial insights SaaS platform for pharmaceutical companies. The company leverages proprietary data-driven and AI-powered methods to identify distinct population subsets and their healthcare providers in the most efficient way possible. With Maptual, pharma sales reps can engage with HCPs, sales managers cancoach their teams, and marketers can gain a deep understanding of their market and develop campaigns that deliver strong business results.
FinSMEs
02/05/2023